NCCN Practice Guidelines for Prostate Cancer
Bahnson, R.R.; Hanks, G.E.; Huben, R.P.; Kantoff, P.; Kozlowski, J.M.; Kuettel, M.; Lange, P.H.; Logothetis, C.; Pow-Sang, J.M.; Roach, M.; Sandler, H.; Scardino, P.T.; Taylor, R.J.; Urban, D.A.; Walsh, P.C.; Wilson, T.G.
Oncology 14(11a): 111-119
2000
ISSN/ISBN: 0890-9091 PMID: 11195405 Document Number: 523390
Systemic therapies for prostate cancer are likely to improve, and as they do, they will have enormous impact on the treatment of high-risk and locally advanced cancers. Further technical improvements in radiotherapy and alternative local modalities, such as cryoablation, are also likely, and will bring even more options for local control. It is certain these guidelines will continue to evolve.